Design and Optimization of Selectivity-Tunable Toll-like Receptor 7/8 Agonists as Novel Antibody-Drug Conjugate Payloads
- J Med Chem. 2024 Sep 12;67(17):15756-15779. doi: 10.1021/acs.jmedchem.4c01384.
- 1. Discovery Chemistry, Merck & Co. Inc., South San Francisco, California 94080, United States.
- 2. Discovery Biologics, Merck & Co. Inc., South San Francisco, California 94080, United States.
- 3. Modeling and Informatics, Merck & Co. Inc., South San Francisco, California 94080, United States.
- 4. Discovery Oncology, Merck & Co. Inc., South San Francisco, California 94080, United States.
- 5. External Discovery Chemistry, Merck & Co. Inc., South San Francisco, California 94080, United States.
Toll-like receptors 7 and 8 are involved in modulating the adaptive and innate immune responses, and their activation has shown promise as a therapeutic strategy in the field of immuno-oncology. While systemic exposure to TLR7/8 agonists can result in poor tolerance, combination therapies and targeted delivery through antibody-drug conjugates (ADCs) can help mitigate adverse effects. Described herein is the identification of a novel and potent series of pyrazolopyrimidine-based TLR7/8 agonists with tunable receptor selectivity. Representative agonists from this series were successfully able to induce the production of various proinflammatory cytokines and chemokines from human peripheral blood mononuclear cells. Anti-HER2-25 and anti-HER2-26 ADCs made from this class of payloads demonstrated mechanism-based activation of TLR7/8 in a THP1/N87 coculture system.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: Toll-like Receptor (TLR)Research Areas: Inflammation/Immunology